Evotec SE (NASDAQ:EVO - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 369,542 shares changed hands during trading, an increase of 296% from the previous session's volume of 93,303 shares.The stock last traded at $5.02 and had previously closed at $5.23.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on EVO shares. Deutsche Bank Aktiengesellschaft raised Evotec from a "hold" rating to a "buy" rating in a research report on Friday, April 12th. HC Wainwright decreased their target price on Evotec from $14.00 to $11.00 and set a "buy" rating for the company in a report on Thursday. Finally, Royal Bank of Canada upgraded shares of Evotec from a "sector perform" rating to an "outperform" rating in a report on Thursday, January 18th.
Check Out Our Latest Research Report on Evotec
Evotec Trading Down 2.5 %
The firm has a 50-day moving average of $7.33 and a 200 day moving average of $8.67.
Institutional Investors Weigh In On Evotec
Large investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC purchased a new position in Evotec in the fourth quarter valued at about $25,000. Optiver Holding B.V. raised its position in shares of Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company's stock valued at $945,000 after purchasing an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC purchased a new position in shares of Evotec during the 4th quarter valued at approximately $53,931,000. 5.81% of the stock is owned by institutional investors and hedge funds.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
